On Monday, Terns Pharmaceuticals Inc (TERN) stock saw a decline, ending the day at $7.85 which represents a decrease of $-0.42 or -5.08% from the prior close of $8.27. The stock opened at $8.35 and ...

A new island designed to attract breeding terns and gulls has been created at Saltholme RSPB. Chris Francis, site manager at ...

The Company granted options to purchase 20,000 shares of Terns common stock to the new employee. The options have a 10-year term and an exercise price per share equal to $8.10, which was the closing ...

With the return of spring comes the start of beach-nesting bird season on beaches up and down the coast, and NSW National ...

On Monday, Terns Pharmaceuticals Inc (TERN) stock saw a decline, ending the day at $8.34 which represents a decrease of $-0.21 or -2.46% from the prior close of $8.55. The stock opened at $8.66 and ...

Terns Pharmaceuticals (NASDAQ:TERN) is a very interesting biotech to look into. That's because it is in the process of developing a drug known as TERN-601 for the treatment of patients with obesity.

Fresh from reporting encouraging results with its oral weight-loss drug, Terns Pharma has moved swiftly ahead with a public offering, seeking to raise upwards of $125 million to fund additional ...

周一，Mizuho将Terns Pharmaceuticals (NASDAQ:TERN)的12个月股票目标价从$10.00上调至$14.00，同时维持其股票评级为"优于大市"。这一调整是在该公司发布了其口服GLP-1受体激动剂TERN-601的1期临床数据之后做出的，该药物旨在治疗肥胖。 Mizuho决定上调目标价反映了基于最近试验积极数据的40%增长。1期临床结果显示出令人鼓舞的疗效，经安慰剂 ...

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug Shares of Terns Pharmaceuticals (NASDAQ: TERN), a clinical-stage company, soared 16.8% after the company announced positive ...

近年来，减肥药市场不断涌现新产品，很多人对于药物的安全性和有效性充满疑虑。TERN-601的临床试验显示出良好的耐受性，且所有参与者均经历了明显的体重减轻，令许多人对这一新药产生了浓厚的兴趣。然而，面对减肥药的良好前景，我们应如何看待并应用这种新技术？

The goats were the first to welcome us. I arrived at the campsite in the hills above Cherry Plain in eastern Rensselaer ...

Short interest in Terns Pharmaceuticals Inc (NASDAQ:TERN) increased during the last reporting period, rising from 1.80M to 2.66M. This put 4.66% of the company's publicly available shares short.